{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:58:40Z","timestamp":1771883920862,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00417-022-05609-6","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T05:02:15Z","timestamp":1646974935000},"page":"3001-3007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Response to netarsudil in goniotomy-treated eyes and goniotomy-na\u00efve eyes: a pilot study"],"prefix":"10.1007","volume":"260","author":[{"given":"Haochen","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa T.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jella A.","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"5609_CR1","first-page":"205","volume":"43","author":"M Choy","year":"2018","unstructured":"Choy M (2018) Pharmaceutical approval update. Pharm Ther 43:205\u2013227","journal-title":"Pharm Ther"},{"key":"5609_CR2","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2147\/OPTH.S154001","volume":"12","author":"L Dasso","year":"2018","unstructured":"Dasso L, Al-Khaled T, Sonty S, Aref AA (2018) Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. Clin Ophthalmol 12:1939\u20131944. https:\/\/doi.org\/10.2147\/OPTH.S154001","journal-title":"Clin Ophthalmol"},{"key":"5609_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","volume":"24","author":"R-F Wang","year":"2015","unstructured":"Wang R-F, Williamson JE, Kopczynski C, Serle JB (2015) Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma 24:51\u201354","journal-title":"J Glaucoma"},{"key":"5609_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/jop.2014.0146","volume":"31","author":"JW Kiel","year":"2015","unstructured":"Kiel JW, Kopczynski CC (2015) Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. J Ocul Pharmacol Ther 31:146\u2013151. https:\/\/doi.org\/10.1089\/jop.2014.0146","journal-title":"J Ocul Pharmacol Ther"},{"key":"5609_CR5","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1167\/iovs.16-20189","volume":"14","author":"R Ren","year":"2016","unstructured":"Ren R, Li G, Le T et al (2016) Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Visc Sci 14:6197\u20136209. https:\/\/doi.org\/10.1167\/iovs.16-20189","journal-title":"Invest Ophthalmol Visc Sci"},{"key":"5609_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2013.05.002","volume":"37","author":"T Inoue","year":"2013","unstructured":"Inoue T, Tanihara H (2013) Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res 37:1\u201312. https:\/\/doi.org\/10.1016\/j.preteyeres.2013.05.002","journal-title":"Prog Retin Eye Res"},{"key":"5609_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejphar.2016.04.002","volume":"787","author":"G Li","year":"2016","unstructured":"Li G, Mukherjee D, Navarro I et al (2016) Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol 787:20\u201331. https:\/\/doi.org\/10.1016\/j.ejphar.2016.04.002","journal-title":"Eur J Pharmacol"},{"key":"5609_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1089\/jop.2017.0138","volume":"34","author":"A Kazemi","year":"2018","unstructured":"Kazemi A, McLaren JW, Kopczynski CC et al (2018) The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther 34:380\u2013386. https:\/\/doi.org\/10.1089\/jop.2017.0138","journal-title":"J Ocul Pharmacol Ther"},{"key":"5609_CR9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1007\/s12325-018-0755-4","volume":"35","author":"SK Dorairaj","year":"2018","unstructured":"Dorairaj SK, Seibold LK, Radcliffe NM et al (2018) 12-month outcomes of goniotomy performed using the Kahook Dual Blade combined with cataract surgery in eyes with medically treated glaucoma. Adv Ther 35:1460\u20131469. https:\/\/doi.org\/10.1007\/s12325-018-0755-4","journal-title":"Adv Ther"},{"key":"5609_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1097\/IJG.0000000000001019","volume":"27","author":"L Salinas","year":"2018","unstructured":"Salinas L, Chaudhary A, Berdahl JP et al (2018) Goniotomy using the Kahook Dual Blade in severe and refractory glaucoma: 6-month outcomes. J Glaucoma 27:849\u2013855. https:\/\/doi.org\/10.1097\/IJG.0000000000001019","journal-title":"J Glaucoma"},{"key":"5609_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2147\/OPTH.S208468","volume":"13","author":"MT Hirabayashi","year":"2019","unstructured":"Hirabayashi MT, Lee D, King JT et al (2019) Comparison of surgical outcomes of 360\u00b0 circumferential trabeculotomy versus sectoral excisional goniotomy with the Kahook Dual Blade at 6 months. Clin Ophthalmol 13:2017\u20132024. https:\/\/doi.org\/10.2147\/OPTH.S208468","journal-title":"Clin Ophthalmol"},{"key":"5609_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/OPTH.S196105","volume":"13","author":"MT Hirabayashi","year":"2019","unstructured":"Hirabayashi MT, King JT, Lee D, An JA (2019) Outcome of phacoemulsification combined with excisional goniotomy using the Kahook Dual Blade in severe glaucoma patients at 6 months. Clin Ophthalmol Auckl NZ 13:715\u2013721. https:\/\/doi.org\/10.2147\/OPTH.S196105","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"5609_CR13","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.2147\/OPTH.S224109","volume":"13","author":"D Lee","year":"2019","unstructured":"Lee D, King J, Thomsen S et al (2019) Comparison of surgical outcomes between excisional goniotomy using the Kahook Dual Blade and iStent trabecular micro-bypass stent in combination with phacoemulsification. Clin Ophthalmol Auckl NZ 13:2097\u20132102. https:\/\/doi.org\/10.2147\/OPTH.S224109","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"5609_CR14","unstructured":"Aerie Pharmaceuticals (2019) Rhopressa\u00ae (netarsudil ophthalmic solution) 0.02% Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208254lbl.pdf. Accessed 12 July 2020"},{"key":"5609_CR15","unstructured":"Organization WH (2004) ICD-10\u202f: international statistical classification of diseases and related health problems\u202f: tenth revision. World Health Organization https:\/\/www.aao.org\/Assets\/5adb14a6-7e5d-42ea-af51-3db772c4b0c2\/636713219263270000\/bc-2568-update-icd-10-quick-reference-guides-glaucoma-final-v2-color-pdf?inline=1. Accessed 13 April 2021."},{"key":"5609_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.exer.2016.01.008","volume":"146","author":"EDK Cha","year":"2016","unstructured":"Cha EDK, Xu J, Gong L, Gong H (2016) Variations in active outflow along the trabecular outflow pathway. Exp Eye Res 146:354\u2013360. https:\/\/doi.org\/10.1016\/j.exer.2016.01.008","journal-title":"Exp Eye Res"},{"key":"5609_CR17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00417-020-04691-y","volume":"258","author":"S Chen","year":"2020","unstructured":"Chen S, Waxman S, Wang C et al (2020) Dose-dependent effects of netarsudil, a Rho-kinase inhibitor, on the distal outflow tract. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 258:1211\u20131216. https:\/\/doi.org\/10.1007\/s00417-020-04691-y","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"5609_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","volume":"204","author":"AS Khouri","year":"2019","unstructured":"Khouri AS, Serle JB, Bacharach J et al (2019) Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol 204:97\u2013104. https:\/\/doi.org\/10.1016\/j.ajo.2019.03.002","journal-title":"Am J Ophthalmol"},{"key":"5609_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E et al (2018) Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol 186:116\u2013127. https:\/\/doi.org\/10.1016\/j.ajo.2017.11.019","journal-title":"Am J Ophthalmol"},{"key":"5609_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0002-9394(99)00237-8","volume":"128","author":"WC Stewart","year":"1999","unstructured":"Stewart WC, Day DG, Sharpe ED et al (1999) Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol 128:692\u2013696. https:\/\/doi.org\/10.1016\/S0002-9394(99)00237-8","journal-title":"Am J Ophthalmol"},{"key":"5609_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","volume":"207","author":"S Asrani","year":"2019","unstructured":"Asrani S, Robin AL, Serle JB et al (2019) Netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol 207:248\u2013257. https:\/\/doi.org\/10.1016\/j.ajo.2019.06.016","journal-title":"Am J Ophthalmol"},{"key":"5609_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","volume":"2","author":"TR Walters","year":"2019","unstructured":"Walters TR, Ahmed IIK, Lewis RA et al (2019) Once-daily netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 Study. Ophthalmol Glaucoma 2:280\u2013289. https:\/\/doi.org\/10.1016\/j.ogla.2019.03.007","journal-title":"Ophthalmol Glaucoma"},{"key":"5609_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","volume":"200","author":"MY Kahook","year":"2019","unstructured":"Kahook MY, Serle JB, Mah FS et al (2019) Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Am J Ophthalmol 200:130\u2013137. https:\/\/doi.org\/10.1016\/j.ajo.2019.01.003","journal-title":"Am J Ophthalmol"},{"key":"5609_CR24","unstructured":"Efficacy | Rhopressa\u00ae (netarsudil ophthalmic solution) 0.02%. https:\/\/rhopressa.com\/hcp\/treatment-results\/. Accessed 17 Nov 2020"},{"key":"5609_CR25","doi-asserted-by":"publisher","first-page":"6509809","DOI":"10.1155\/2016\/6509809","volume":"2016","author":"P Harasymowycz","year":"2016","unstructured":"Harasymowycz P, Birt C, Gooi P et al (2016) Medical management of glaucoma in the 21st century from a Canadian perspective. J Ophthalmol 2016:6509809. https:\/\/doi.org\/10.1155\/2016\/6509809","journal-title":"J Ophthalmol"},{"key":"5609_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.5694\/mja2.50020","volume":"210","author":"J Lusthaus","year":"2019","unstructured":"Lusthaus J, Goldberg I (2019) Current management of glaucoma. Med J Aust 210:180\u2013187. https:\/\/doi.org\/10.5694\/mja2.50020","journal-title":"Med J Aust"},{"key":"5609_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/ICU.0000000000000623","volume":"31","author":"CEC Young","year":"2020","unstructured":"Young CEC, Seibold LK, Kahook MY (2020) Cataract surgery and intraocular pressure in glaucoma. Curr Opin Ophthalmol 31:15\u201322. https:\/\/doi.org\/10.1097\/ICU.0000000000000623","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05609-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T10:03:38Z","timestamp":1661508218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05609-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5609"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05609-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"1 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (IRB #2014107) was approved by the University of Missouri Institutional Review Board, which granted a waiver of consent for retrospective analysis of existing health records. This study followed the tenets of the Declaration of Helsinki, and patient data were collected and maintained confidentially in compliance with the Health Insurance Portability and Accountability Act.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.A. is a consultant for Aerie Pharmaceuticals and New World Medical. All other authors have no conflicts of interest to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}